Keywords: سرطان پروستات مقاوم به کاستراکت; Castrate-resistant prostate cancer; CRPC; Androgen deprivation therapy; ADT; LHRH; Immune therapy; Skeletal-related event (SRE);
مقالات ISI سرطان پروستات مقاوم به کاستراکت (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: سرطان پروستات مقاوم به کاستراکت; AR; androgen receptor; ARPI; androgen receptor pathway inhibition; CRPC; castrate-resistant prostate cancer; PCa; prostate cancer; BPH; benign prostate hyperplasia; ERα; estrogen receptor-α; PR; progesterone receptor; PRA; PR isoform A; PRB; PRB isoform
Keywords: سرطان پروستات مقاوم به کاستراکت; Prostate cancer; Castrate-resistant prostate cancer; Prostate; Cancer-specific death; Prostate cancer progression; Biomarker;
Keywords: سرطان پروستات مقاوم به کاستراکت; Non-coding RNA; Biomarkers; Oncomirs; Tumor suppressor; Androgen receptor; Castrate-resistant prostate cancer; AR; androgen receptor; ARHI; Ras homolog member I; BCR; biochemical recurrence; BPH; benign prostatic hyperplasia; BTG-2; B-cell translocation g
27-hydroxycholesterol: A novel player in molecular carcinogenesis of breast and prostate cancer
Keywords: سرطان پروستات مقاوم به کاستراکت; 27-OHC; 27-hydroxycholesterol; ADT; androgen deprivation therapy; AR; androgen receptor; ATF4; Activating Transcription Factor 4; ATF6; Activating Transcription Factor 6; C/EBP; CCAAT / Enhancer binding proteins; CHOP; C/EBP homologous protein; CIP2A; can
Keywords: سرطان پروستات مقاوم به کاستراکت; AA; accelerated approval; ALL; acute lymphoblastic leukemia; CCyR; complete cytogenetic response; CLL; chronic lymphocytic lymphoma; CML; chronic myeloid leukemia; CRC; colorectal carcinoma; CR; complete response; CRi; complete response with incomplete bl
Keywords: سرطان پروستات مقاوم به کاستراکت; castrate-resistant prostate cancer; EORTC-8D; EQ-5D-5L; HRQOL; utilities;
Osteonecrosis of the Jaw in a Patient With Bone Metastatic Prostate Cancer After Long-term Bisphosphonate Treatment With Severe Deterioration Following Radium-223
Keywords: سرطان پروستات مقاوم به کاستراکت; Adverse event; Bone metastases; Castrate-resistant prostate cancer; Combination therapy; Jaw necrosis;
Retrospective Review of Percutaneous Image-Guided Ablation of Oligometastatic Prostate Cancer: A Single-Institution Experience
Keywords: سرطان پروستات مقاوم به کاستراکت; ADT; androgen-deprivation therapy; CRPC; castrate-resistant prostate cancer; PET; positron emission tomography; PFS; progression free survival; PSA; prostate-specific antigen; SBRT; stereotactic body radiation therapy;
Acute Promyelocytic Leukemia After Treatment of Metastatic Castration-Resistant Prostate Cancer With Radium-223
Keywords: سرطان پروستات مقاوم به کاستراکت; Acute promyelocytic leukemia; Bone metastases; Castrate-resistant prostate cancer; Leukemia; Radium-223;
Regulated expression of the TPβ isoform of the human T prostanoid receptor by the tumour suppressors FOXP1 and NKX3.1: Implications for the role of thromboxane in prostate cancer
Keywords: سرطان پروستات مقاوم به کاستراکت; 5-aza-dC; 5-aza-2â²-deoxycytidine; AA; arachidonic acid; ADT; androgen deprivation therapy; AR; androgen receptor; BCR; biochemical recurrence; ChIP; chromatin immunoprecipitation; CNA; copy number alteration; COX; cyclooxygenase/prostaglandin G2/H2 synt
External Validation of a Prognostic Model Predicting Overall Survival in Metastatic Castrate-resistant Prostate Cancer Patients Treated with Abiraterone
Keywords: سرطان پروستات مقاوم به کاستراکت; Castrate-resistant prostate cancer; Prognosis; Abiraterone;
Wine polyphenols exert antineoplasic effect on androgen resistant PC-3 cell line through the inhibition of the transcriptional activity of COX-2 promoter mediated by NF-κβ
Keywords: سرطان پروستات مقاوم به کاستراکت; Castrate-resistant prostate cancer; PC-3 cell line; Resveratrol; Polyphenols; COX-2; NF-κβCáncer de próstata resistente a castración; Línea celular PC-3; Resveratrol; Polifenoles; COX-2; NF-κβ
Prostate cancer
Keywords: سرطان پروستات مقاوم به کاستراکت; Active surveillance; androgen-deprivation therapy; castrate-resistant prostate cancer; prostate cancer; prostate specific antigen; radical prostatectomy; radical radiotherapy
Palliative Care in Castrate-Resistant Prostate Cancer
Keywords: سرطان پروستات مقاوم به کاستراکت; Palliative care; Castrate-resistant prostate cancer; Symptom management;
Cabazitaxel: Evidence and clinical experience
Keywords: سرطان پروستات مقاوم به کاستراکت; Prostate; Castrate-resistant prostate cancer; Docetaxel; Second-line treatment; Cabazitaxel; Abiraterone; Toxicity; Performance status;
Evolution of docetaxel-based therapy for metastatic castrate-resistant prostate cancer
Keywords: سرطان پروستات مقاوم به کاستراکت; Castrate-resistant prostate cancer; Chemotherapy; Docetaxel
Beyond castration and chemotherapy: Novel approaches to targeting androgen-driven pathways
Keywords: سرطان پروستات مقاوم به کاستراکت; MDV3100; Abiraterone; Phase III; Castrate-resistant prostate cancer; Hormone-refractory prostate cancer; Prostate cancer; Targeted therapy; Novel therapy; Biologic therapy;
Treatment Decisions for Advanced Genitourinary Cancers: From Symptoms to Risk Assessment
Keywords: سرطان پروستات مقاوم به کاستراکت; Advanced bladder cancer; Advanced renal cell carcinoma; Case studies; Castrate-resistant prostate cancer; Docetaxel; Genitourinary cancers; Nomogram; Retreatment; Risk assessment; Senior adult patients